Emcure Pharmaceuticals
EMCURENSE

Emcure Pharmaceuticals

₹1,998.703.50 (0.18%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
1,985.00
Today’s high
2,024.90
52 week low
1,260.00
52 week high
2,048.00
Open price
1,995.20
Previous close
1,995.20
Live volume
97,589
Lower circuit
1,798.90
Upper circuit
2,198.50

Fundamentals

Market Cap
₹37,887Cr
ROE
18.67%
P/E Ratio(TTM)
37.18
EPS(TTM)
53.72
P/B Ratio
7.65
Dividend Yield
0.18%
Industry P/E
37.01
Book Value
260.97
Debt to Equity
0.31
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
JUN '26
Revenue (Cr)
₹2,583
+4.40%
Profit (Cr)
₹292
+20.00%
07501.5k2.25k3k
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue growthValue
1Y (TTM)+23%
3Y CAGR+10%
Profit growthValue
1Y (TTM)+36%
3Y CAGR0%

About

Emcure Pharmaceuticals Limited is a research-driven pharmaceutical company, developing and manufacturing affordable and innovative medicines across various therapeutic areas.;
CEO/MD
Mr. Satish Mehta
Founded in
1981
NSE symbol
EMCURE

Shareholding pattern

Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Shareholder details

Mutual Funds Invested (4)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹5,527.50
-71.00 (1.27%)
L
    H
    65,880.3228.024.77
    Abbott IndiaABBOTINDIA
    ₹28,020.00
    +485.00 (1.76%)
    L
      H
      59,518.7038.3512.47
      ₹1,748.40
      +62.60 (3.71%)
      L
        H
        44,380.4837.495.5
        ₹2,601.90
        +0.90 (0.03%)
        L
          H
          43,993.9041.1919.4
          Livesquawk
          Emcure Pharma's Sanand plant in Gujarat gains US FDA approval for specific formulations.
          Livesquawk
          Jefferies reiterates Buy on Emcure Pharma with ₹2,320 target, citing strong 10% revenue and 12% EBITDA beats. Domestic growth recovered 10% YoY; international markets exceeded estimates by 8-24%, driving FY27-29 EPS upgrade by 6%.
          Livesquawk
          Emcure Pharma's Q1 consolidated net profit rose to ₹3B from ₹2B YoY. The YoY improvement represents a growth of approximately 50%.
          Livesquawk
          ICMR licenses three biomedical technologies to Emcure for commercial use, including anti-HPV treatment. Technologies also include advanced vaccines for typhoid, paratyphoid, and Shigella.
          2026
          6
          Aug
          Quarterly Result
          Release date
          5
          May
          Annual Result
          Release date
          4
          Feb
          Quarterly Result
          Release date
          2025
          11
          Nov
          Quarterly Result
          Release date

          14
          Aug
          Dividend
          Ex date
          ₹3.00
          per share

          For each share you hold, you will receive ₹3.00
          Dividend amount₹3.00 per share
          Dividend TypeFinal
          Ex Date14 Aug ‘25
          Record Date14 Aug ‘25
          Announcement date22 May ‘25
          7
          Aug
          Quarterly Result
          Release date

          22
          May
          Dividend
          Announced
          ₹3.00
          per share

          For each share you hold, you will receive ₹3.00
          Dividend amount₹3.00 per share
          Dividend TypeFinal
          Ex Date14 Aug ‘25
          Record Date14 Aug ‘25
          Announcement date22 May ‘25
          Events calendar
          View upcoming events in other stocks